118 related articles for article (PubMed ID: 38531802)
1. Formononetin Restrains Tumorigenesis of Breast Tumor by Restraining STING-NF-κB and Interfering with the Activation of PD-L1.
Liu H; Wang Z; Liu Z
Discov Med; 2024 Mar; 36(182):613-620. PubMed ID: 38531802
[TBL] [Abstract][Full Text] [Related]
2. Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation.
Wang JY; Jiang MW; Li MY; Zhang ZH; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Jin HL; Ma J; Jin Y; Zuo HX; Jin X
J Nutr Biochem; 2022 Feb; 100():108899. PubMed ID: 34748924
[TBL] [Abstract][Full Text] [Related]
3. Brazilein inhibits epithelial-mesenchymal transition (EMT) and programmed death ligand 1 (PD-L1) expression in breast cancer cells.
Wudtiwai B; Kodchakorn K; Shwe TH; Pothacharoen P; Phitak T; Suninthaboonrana R; Kongtawelert P
Int Immunopharmacol; 2023 May; 118():109988. PubMed ID: 36933493
[TBL] [Abstract][Full Text] [Related]
4. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients.
Vasiyani H; Mane M; Rana K; Shinde A; Roy M; Singh J; Gohel D; Currim F; Srivastava R; Singh R
Apoptosis; 2022 Dec; 27(11-12):961-978. PubMed ID: 36018392
[TBL] [Abstract][Full Text] [Related]
5. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936263
[TBL] [Abstract][Full Text] [Related]
9. MiRNA-138-5p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis.
Rasoolnezhad M; Safaralizadeh R; Hosseinpourfeizi MA; Banan-Khojasteh SM; Baradaran B
Eur J Pharmacol; 2021 Apr; 896():173933. PubMed ID: 33545160
[TBL] [Abstract][Full Text] [Related]
10. Activation of lncRNA lnc-SLC4A1-1 induced by H3K27 acetylation promotes the development of breast cancer via activating CXCL8 and NF-kB pathway.
Yi T; Zhou X; Sang K; Huang X; Zhou J; Ge L
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3765-3773. PubMed ID: 31556319
[TBL] [Abstract][Full Text] [Related]
11. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
Kim SL; Choi HS; Lee DS
Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.
Chen J; Zeng J; Xin M; Huang W; Chen X
Horm Metab Res; 2011 Sep; 43(10):681-6. PubMed ID: 21932171
[TBL] [Abstract][Full Text] [Related]
15. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways.
Zhou R; Xu L; Ye M; Liao M; Du H; Chen H
Horm Metab Res; 2014 Oct; 46(11):753-60. PubMed ID: 24977660
[TBL] [Abstract][Full Text] [Related]
16. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
17. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Coombs MRP; Harrison ME; Hoskin DW
Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
[TBL] [Abstract][Full Text] [Related]
18. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.
Cai H; Yan L; Liu N; Xu M; Cai H
Biomed Pharmacother; 2020 Mar; 123():109790. PubMed ID: 31896065
[TBL] [Abstract][Full Text] [Related]
19. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
Front Immunol; 2021; 12():802795. PubMed ID: 35069587
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF-β1/SMAD4 expression.
Chen MJ; Wang YC; Wang L; Shen CJ; Chen CY; Lee H
Thorac Cancer; 2022 May; 13(9):1322-1332. PubMed ID: 35373505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]